Spire Healthcare Group
SPI · Main Market · Health Care · mcap £990m · 247.0p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 12 Oct 26 | Holding | Holding(s) in Company | |
| 09 Oct 26 | Holding | Holding(s) in Company | |
| 02 Oct 26 | Holding | Holding(s) in Company | |
| 02 Oct 26 | Holding | Holding(s) in Company | |
| 01 Oct 26 | Holding | Holding(s) in Company | |
| 30 Sep 26 | Results | Results for the six months ended 30 June 2026
H1 revenue stable but adjusted EBITDA down 16.6% due to NHS funding slowdown and cost inflation; private revenues grew. |
+0.4% |
| 29 Sep 26 | Holding | Holding(s) in Company | |
| 29 Sep 26 | Publication of Scheme Document Announcement
Scheme document published for recommended cash acquisition by consortium led by Toscafund, THCP and Ares. |
−0.2% | |
| 28 Sep 26 | Holding | Holding(s) in Company | |
| 24 Sep 26 | Holding | Holding(s) in Company | |
| 11 Sep 26 | Routine | Form 8 (DD) - Spire Healthcare Group plc | |
| 11 Sep 26 | Spire Healthcare - Application of Rule 4.2(c)
Takeover Panel imposed restrictions on Bidco after undisclosed share sale by concert party during offer period. |
−0.2% | |
| 10 Sep 26 | Holding | Holding(s) in Company | |
| 07 Sep 26 | Board and Management Changes
CEO Justin Ash retiring after nine years; Sir David Sloman assumes interim CEO role; Debbie White becomes interim Chair. |
+2.9% | |
| 07 Sep 26 | Offer | Recommended Offer for Spire Healthcare Group plc
Toscafund-led consortium to acquire Spire Healthcare for 250p per share in cash. |
+2.9% |
| 04 Sep 26 | Further extension of the PUSU Deadline
PUSU deadline for Toscafund offer decision extended by one day to 5 September 2026. |
−1.2% | |
| 03 Sep 26 | Further Extension of the PUSU Deadline
Takeover Panel grants one-day extension to Toscafund's deadline to announce firm offer or walk away. |
+2.1% | |
| 21 Aug 26 | Results | Change to Interim Results announcement date
Spire Healthcare Group plc (LSE: SPI), a leading independent healthcare group in the UK, announces that its Interim Results for the six months ended 30 June 2026 are expected to be released by 30 September 2026, and not |
−0.4% |
| 21 Aug 26 | Further extension of the PUSU Deadline
Toscafund granted extension to 3 September 2026 to announce firm offer decision at 250p per share. |
−0.4% | |
| 06 Aug 26 | Further extension of the PUSU Deadline
Toscafund granted further extension to 21 August 2026 to announce firm intention on 250p per share offer for Spire Healthcare. |
+1.1% | |
| 21 Jul 26 | Notice of Interim Results
Spire Healthcare Group plc (LSE: SPI), a leading independent healthcare group in the UK, will announce its interim results for the six months ended 30 June 2026 on 9 September 2026. |
+3.7% | |
| 15 Jul 26 | Spire Healthcare announced as exclusive Team GB Official Healthcare Services Partner
Spire Healthcare becomes exclusive Official Healthcare Services Partner for Team GB through 2028 Los Angeles Olympics. |
+0.2% | |
| 14 Jul 26 | Board change | Chair Succession
Chair Sir Ian Cheshire to step down by 30 September 2026; Debbie White appointed Chair-Designate. |
+0.5% |
| 09 Jul 26 | Further extension of the PUSU Deadline
Toscafund granted extension to 6 August 2026 for announcement of firm 250p per share cash offer for Spire Healthcare. |
+1.9% | |
| 25 Jun 26 | Further extension to deadline under Rule 2.6(c)
Toscafund takeover proposal deadline extended to 9 July 2026 as due diligence and discussions continue. |
−1.8% | |
| 11 Jun 26 | Extension to deadline
Takeover Panel extends deadline for Toscafund to announce firm offer to 25 June 2026. |
+2.6% | |
| 28 May 26 | Routine | Form 8 (OPD) - Spire Healthcare Group plc | |
| 19 May 26 | Notification of Transactions
Executive Directors Justin Ash and Harbant Samra exercised vested share awards on 18 May 2026. |
−1.4% | |
| 19 May 26 | Routine | Form 8 (DD) - Spire Healthcare Group plc | |
| 19 May 26 | Routine | Form 8 (DD) - Spire Healthcare Group plc | |
| 14 May 26 | Routine | Result of AGM | |
| 14 May 26 | Disclosure Table
The following are today's changes to the Disclosure Table: |
+49.3% | |
| 14 May 26 | Trading update | FY26 trading update to April and full-year outlook
Trading to April 2026 in line with expectations; FY26 adjusted EBITDA guidance reconfirmed broadly in line with FY25. |
+49.3% |
| 14 May 26 | Offer | Statement regarding possible offer
Toscafund proposes 250p per share cash offer for entire company, Board minded to recommend. |
+49.3% |
| 14 Apr 26 | Routine | Dividend Declaration | |
| 09 Apr 26 | Routine | Notice of AGM and Annual Financial Report | |
| 23 Mar 26 | Disclosure Table
The following are today's changes to the Disclosure Table: |
−22.5% | |
| 23 Mar 26 | Update on Strategic Review
Takeover talks with Bridgepoint and Triton have ended; board continues exploring other options. |
−22.5% | |
| 20 Mar 26 | Announcement made following a related announcement
Triton Investments confirms it does not intend to make a firm offer for Spire Healthcare. |
+6.7% | |
| 20 Mar 26 | Statement regarding Spire Healthcare Group
Bridgepoint confirms it will not make an offer for Spire Healthcare following formal sale process. |
+6.7% | |
| 20 Mar 26 | Disclosure Table
The following are today's changes to the Disclosure Table: |
+6.7% | |
| 18 Mar 26 | Director dealing | Director/PDMR Shareholding | |
| 05 Mar 26 | Results | Final Results
FY25 revenue grew 4.5% to £1,579.8m with EBITDA up 3.2%, offset by NHS commissioning pressures and strategic review costs. |
−2.5% |
| 18 Feb 26 | Extension to deadline under Rule 2.6(c)
Takeover Panel grants extension to 21 March 2026 for Bridgepoint and Triton to announce offers or withdrawal. |
+0.0% | |
| 26 Jan 26 | Statement regarding media speculation
Bridgepoint and Triton confirmed as parties in takeover discussions following September 2025 strategic review. |
+17.8% | |
| 12 Jan 26 | Routine | Block listing Interim Review | |
| 09 Jan 26 | Director Declaration
Spire Healthcare Group plc (LSE: SPI) ('Spire Healthcare', 'the Group' or 'the Company'), a leading independent healthcare group in the UK, announces that Jill Anderson, a Non-Executive Director of the Company, has been |
+0.3% | |
| 11 Dec 25 | Holding | Holding(s) in Company | |
| 11 Dec 25 | Holding | Holding(s) in Company | |
| 03 Dec 25 | Trading update | Trading Update
Group revenue up 3.6% to October 2025; FY25 EBITDA expected at bottom of £270-285m guidance due to NHS commissioning slowdown. |
−16.9% |
Company filings. Not investment advice.